Literature DB >> 19497498

Blunt traumatic aortic injury: initial experience with endovascular repair.

Ali Azizzadeh1, Kourosh Keyhani, Charles C Miller, Sheila M Coogan, Hazim J Safi, Anthony L Estrera.   

Abstract

OBJECTIVES: Endovascular treatment of traumatic aortic injury (TAI) is an alternative to open repair (OR) in patients with blunt trauma. We report our initial experience after integration of endovascular repair using thoracic devices.
METHODS: A retrospective review of a prospectively collected institutional trauma registry was performed. Between September 2005 and November 2008, 71 patients with TAI presented to our institution. Based on imaging, TAIs were classified into grade 1-4 in severity. These included: grade 1, intimal tear; grade 2, intramural hematoma; grade 3, aortic pseudoaneurysm; and grade 4, free rupture. Initial management included resuscitation, blood pressure control, and treatment of associated injuries. After stabilization, all patients were considered for thoracic endovascular aortic repair (TEVAR) using a thoracic device. If contraindicated, candidates underwent OR. Outcome measures were mortality, stroke, paraplegia, intensive care unit (ICU), and hospital stay.
RESULTS: The mean age was 39.8 years, with 50 males. The mean injury severity score (ISS) was 42.6. Nineteen (27%) patients with a mean ISS of 60 died shortly after arrival prior to any vascular intervention. Ten (14%) patients with grade 1 injuries were managed medically. The remaining 42 (59%) patients with grade 2 and 3 injuries underwent repair. Median interval between admission and repair was 4.3 days (range, 0-109 days). Fifteen (21%) patients with a mean ISS of 34.4 underwent OR with no mortality, stroke, or paraplegia. Twenty-seven (38%) patients with a mean ISS of 36.7 underwent TEVAR with no mortality or paraplegia. One TEVAR patient suffered a perioperative stroke. Twenty-two patients had a TAG (W.L. Gore & Associates, Flagstaff, Ariz) device. Four patients had a Talent Thoracic (Medtronic Vascular, Santa Rosa, Calif), and 1 patient had an Excluder (W.L. Gore) device. The left subclavian artery was covered in 13 (48%) patients. Patients who underwent TEVAR were older than those who had OR (47.8 vs 31.1 years, P < .006). The aortic diameter proximal to the injury was larger in the TEVAR group (24.4 vs 19.6 mm, P < .0001). There was no difference in the mean ICU or hospital length of stay between the two groups. Mortality correlated with the ISS score (P < .0001). Median follow-up time was 19.4 months (range, 0-27). Only 56% of the TEVAR patients were fully compliant with their surveillance imaging protocol.
CONCLUSION: In this initial experience, the results of TEVAR did not differ from OR. Long-term follow-up is required to determine the effectiveness of this treatment strategy. Adherence to follow-up imaging protocols is challenging in this patient population. Next generation devices will make TEVAR applicable to a wider range of patients.

Entities:  

Mesh:

Year:  2009        PMID: 19497498     DOI: 10.1016/j.jvs.2009.02.234

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  51 in total

1.  Blunt aortic injuries in the new era: radiologic findings and polytrauma risk assessment dictates management strategy.

Authors:  Rachel Elizabeth Payne; Rachel Michelle Nygaard; Joss Dean Fernandez; Prateek Sahgal; Chad John Richardson; Mohammad Bashir; Kalpaj Parekh; Panos Nicolas Vardas; Yoshikazu Suzuki; Joel Corvera; Jon Christopher Krook; Domenico Calcaterra
Journal:  Eur J Trauma Emerg Surg       Date:  2019-06-21       Impact factor: 3.693

2.  Natural history of minimal aortic injury following blunt thoracic aortic trauma.

Authors:  Biniam Kidane; Daniel Abramowitz; Jeremy R Harris; Guy DeRose; Thomas L Forbes
Journal:  Can J Surg       Date:  2012-12       Impact factor: 2.089

3.  Late Radiological and Clinical Outcomes of Traumatic Thoracic Aortic Injury Managed with Thoracic Endovascular Aortic Repair.

Authors:  M Khashram; Q He; T H Oh; A Khanafer; I A Wright; T M Vasudevan; A S N Lo; J A Roake; I Civil
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

4.  Efficacy and safety of TEVAR with debranching technique for blunt traumatic aortic injury in patients with severe multiple trauma.

Authors:  Kenichiro Uchida; Tetsuro Nishimura; Hiromasa Yamamoto; Yasumitsu Mizobata
Journal:  Eur J Trauma Emerg Surg       Date:  2019-04-03       Impact factor: 3.693

5.  Mid-term outcomes of endovascular repair for traumatic thoracic aortic injury: a single-center experience.

Authors:  Shin-Ah Son; Hanna Jung; Joon Yong Cho; Tak-Hyuk Oh; Young Woo Do; Kyoung Hoon Lim; Gun-Jik Kim
Journal:  Eur J Trauma Emerg Surg       Date:  2019-06-10       Impact factor: 3.693

6.  A case of traumatic thoracic aorta rupture - A life threatening emergency.

Authors:  Rupesh Kumar; Javid Raja; Ganesh Kumar Munirathinam; Anand Kumar Mishra; Rana Sandeep Singh; Shyam Kumar Singh Thingnam
Journal:  J Cardiovasc Thorac Res       Date:  2019-05-28

7.  Endovascular repair of thoracic aortic injury: current thoughts and technical considerations.

Authors:  W Darrin Clouse
Journal:  Semin Intervent Radiol       Date:  2010-03       Impact factor: 1.513

Review 8.  Management of traumatic aortic rupture.

Authors:  Ken-ichi Watanabe; Ikuo Fukuda; Yasushi Asari
Journal:  Surg Today       Date:  2013-01-23       Impact factor: 2.549

9.  Natural history of grade I-II blunt traumatic aortic injury.

Authors:  Michael J Osgood; Josh M Heck; Eric J Rellinger; Stacey L Doran; C Louis Garrard; Raul J Guzman; Thomas C Naslund; Jeffery B Dattilo
Journal:  J Vasc Surg       Date:  2013-12-15       Impact factor: 4.268

Review 10.  Dual-phase CT for the assessment of acute vascular injuries in high-energy blunt trauma: the imaging findings and management implications.

Authors:  Francesca Iacobellis; Anna M Ierardi; Maria A Mazzei; Alberto Magenta Biasina; Gianpaolo Carrafiello; Refky Nicola; Mariano Scaglione
Journal:  Br J Radiol       Date:  2016-02-17       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.